Working... Menu

[S,S]-Reboxetine Add-On Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00334685
Recruitment Status : Terminated (The DMC terminated the study on the basis of futility (insufficient clinical response).)
First Posted : June 8, 2006
Last Update Posted : July 17, 2008
Information provided by:

Brief Summary:
The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with [S,S]-Reboxetine against pregabalin monotherapy in patients with PHN

Condition or disease Intervention/treatment Phase
Pain Drug: [S,S]-Reboxetine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 354 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: [S,S]-Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN) Concomitantly Treated With Pregabalin.
Study Start Date : July 2006

Primary Outcome Measures :
  1. The numerical pain intensity rating scale is used to assess pain and a change from baseline in pain score for week 10 will be calculated

Secondary Outcome Measures :
  1. The mean endpoint (week 10) sleep interference score change from baseline
  2. Analysis of the Medical Outcomes Study Sleep Scale
  3. Analysis of the Patient Global Impression of Change
  4. Analysis of the Neuropathic Pain Symptom Inventory

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have pain present for more than 3 months after the healing of shingles skin rash
  • Patients at screening must have a score >/=40 mm on the pain visual analogue scale

Exclusion Criteria:

  • Patients with significant renal and hepatic impairment
  • Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
  • Patients with clinically abnormal electrocardiogram

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00334685

  Show 83 Study Locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure, Pfizer, Inc. Identifier: NCT00334685     History of Changes
Other Study ID Numbers: A6061021
First Posted: June 8, 2006    Key Record Dates
Last Update Posted: July 17, 2008
Last Verified: July 2008

Additional relevant MeSH terms:
Layout table for MeSH terms
Antidepressive Agents
Psychotropic Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs